CN112638905A - 作为rip2激酶抑制剂的喹唑啉类衍生物 - Google Patents
作为rip2激酶抑制剂的喹唑啉类衍生物 Download PDFInfo
- Publication number
- CN112638905A CN112638905A CN201980056903.2A CN201980056903A CN112638905A CN 112638905 A CN112638905 A CN 112638905A CN 201980056903 A CN201980056903 A CN 201980056903A CN 112638905 A CN112638905 A CN 112638905A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- optical isomer
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
公开了一类喹唑啉类衍生物,具体公开式(Ⅰ)所示化合物及其药学上可接受的盐及其在制备RIP2激酶抑制剂的应用。
Description
PCT国内申请,说明书已公开。
Claims (24)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018109898390 | 2018-08-28 | ||
CN201810989839 | 2018-08-28 | ||
CN2019101228253 | 2019-02-19 | ||
CN201910122825 | 2019-02-19 | ||
PCT/CN2019/102999 WO2020043122A1 (zh) | 2018-08-28 | 2019-08-28 | 作为rip2激酶抑制剂的喹唑啉类衍生物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112638905A true CN112638905A (zh) | 2021-04-09 |
Family
ID=69642897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980056903.2A Pending CN112638905A (zh) | 2018-08-28 | 2019-08-28 | 作为rip2激酶抑制剂的喹唑啉类衍生物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112638905A (zh) |
WO (1) | WO2020043122A1 (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058267A1 (en) * | 2002-12-23 | 2004-07-15 | Ariad Pharmaceuticals, Inc. | Heterocycles and uses thereof |
WO2013025958A1 (en) * | 2011-08-18 | 2013-02-21 | Glaxo Group Limited | Amino quinazolines as kinase inhibitors |
WO2014043446A1 (en) * | 2012-09-13 | 2014-03-20 | Glaxosmithkline Llc | Prodrugs of amino quinazoline kinase inhibitor |
WO2014128622A1 (en) * | 2013-02-21 | 2014-08-28 | Glaxosmithkline Intellectual Property Development Limited | Quinazolines as kinase inhibitors |
WO2016172134A2 (en) * | 2015-04-22 | 2016-10-27 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
WO2017046036A1 (en) * | 2015-09-14 | 2017-03-23 | Glaxosmithkline Intellectual Property Development Limited | Compounds for the modulation of rip2 kinase activity |
WO2017182418A1 (en) * | 2016-04-20 | 2017-10-26 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising ripk2 inhibitors |
-
2019
- 2019-08-28 CN CN201980056903.2A patent/CN112638905A/zh active Pending
- 2019-08-28 WO PCT/CN2019/102999 patent/WO2020043122A1/zh active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058267A1 (en) * | 2002-12-23 | 2004-07-15 | Ariad Pharmaceuticals, Inc. | Heterocycles and uses thereof |
WO2013025958A1 (en) * | 2011-08-18 | 2013-02-21 | Glaxo Group Limited | Amino quinazolines as kinase inhibitors |
WO2014043446A1 (en) * | 2012-09-13 | 2014-03-20 | Glaxosmithkline Llc | Prodrugs of amino quinazoline kinase inhibitor |
WO2014128622A1 (en) * | 2013-02-21 | 2014-08-28 | Glaxosmithkline Intellectual Property Development Limited | Quinazolines as kinase inhibitors |
WO2016172134A2 (en) * | 2015-04-22 | 2016-10-27 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
WO2017046036A1 (en) * | 2015-09-14 | 2017-03-23 | Glaxosmithkline Intellectual Property Development Limited | Compounds for the modulation of rip2 kinase activity |
WO2017182418A1 (en) * | 2016-04-20 | 2017-10-26 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising ripk2 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
WO2020043122A1 (zh) | 2020-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105555782B (zh) | 喹唑啉衍生物及其制备方法 | |
JP6267806B2 (ja) | 2,4−二置換ベンゼン−1,5−ジアミン誘導体およびその使用ならびにそれから製造される医薬組成物および薬用組成物 | |
JP2023523640A (ja) | ベンゾチアゾリルビアリール系化合物、その調製方法及び使用 | |
CN109071448A (zh) | Ask1抑制剂及其制备方法和应用 | |
TWI723131B (zh) | 6‐雜環基‐4‐嗎啉‐4‐芳基吡啶‐2‐酮化合物 | |
TWI641602B (zh) | 單環吡啶衍生物 | |
CN112778276A (zh) | 作为shp2抑制剂的化合物及其应用 | |
NO169070B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive n-heterosyklisk-n-(4-piperidyl)-amider | |
JP7162741B2 (ja) | 新規なヘテロサイクリックアミン誘導体およびこれを含む薬学組成物 | |
CN116888108B (zh) | 新型egfr降解剂 | |
TW202115035A (zh) | 雜環醯胺類化合物及其製備方法和應用 | |
CN109661395A (zh) | Pde4抑制剂 | |
CN105732602A (zh) | 作为ns4b抑制剂的苯并呋喃类似物 | |
JP2022511236A (ja) | 置換キナゾリノン誘導体、及びmGluR4のポジティブアロステリック調節剤としてのその使用 | |
EA037876B1 (ru) | Соединение в виде аминозамещенного шестичленного гетероциклического кольца с гетероатомом азота, его получение и использование | |
CN112638905A (zh) | 作为rip2激酶抑制剂的喹唑啉类衍生物 | |
CN114845996A (zh) | 一种含苯环的化合物及其应用 | |
CA3235504A1 (en) | Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 | |
CN113214240B (zh) | 作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用 | |
CN112538084B (zh) | 新颖的kras g12c蛋白抑制剂及其制备方法和用途 | |
WO2021121390A1 (zh) | 杂环化合物及其药物组合物、制备方法、中间体和应用 | |
KR20240019071A (ko) | N2-페닐피리미딘-2,4-디아민 화합물, 및 그 제조 방법 및 사용 방법 | |
ES2642805T3 (es) | Sal de un derivado del ácido pirrolidín-3-ilacético y cristales de esta | |
KR20010031724A (ko) | 페닐-알킬-이미다졸 유형의 h₃ 수용체 리간드 | |
CN113474318A (zh) | 用作血浆激肽释放酶抑制剂的双环烷类化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210409 |